{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:13:20Z","timestamp":1778314400108,"version":"3.51.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Agence Nationale de Recherches sur le SIDA et les H\u00e9patites virales"},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/jac\/dkz021","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T15:10:18Z","timestamp":1547133018000},"page":"1368-1375","source":"Crossref","is-referenced-by-count":18,"title":["Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients"],"prefix":"10.1093","volume":"74","author":[{"given":"Anne-Genevieve","family":"Marcelin","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Grude","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"INSERM, IAME, UMR 1137, F-75018 Paris, France; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, F-75018 Paris, France; AP-HP, H\u00f4pital Bichat, Laboratoire de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantxika","family":"Bellecave","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Laboratoire de Virologie, Universit\u00e9 Bordeaux, CNRS UMR 5234, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Le Guen","sequence":"additional","affiliation":[{"name":"CHU de Nantes, Laboratoire de Virologie, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Pallier","sequence":"additional","affiliation":[{"name":"CHU Paul Brousse, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5844","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Raymond","sequence":"additional","affiliation":[{"name":"INSERM U1043 Toulouse, F-31300 France and Laboratoire de Virologie, CHU Toulouse Purpan, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mirand","sequence":"additional","affiliation":[{"name":"CHU de Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bocket","sequence":"additional","affiliation":[{"name":"CHU de Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djeneba Bocar","family":"Fofana","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis, d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Saint Antoine, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"CHU Saint Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Mont\u00e8s","sequence":"additional","affiliation":[{"name":"CHU Saint-Eloi, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Jeulin","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, CHRU de Nancy Brabois, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mourez","sequence":"additional","affiliation":[{"name":"CHU de Rouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Fafi-Kremer","sequence":"additional","affiliation":[{"name":"CHU de Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Amiel","sequence":"additional","affiliation":[{"name":"AP-HP, CHU Tenon, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Roussel","sequence":"additional","affiliation":[{"name":"CHU d\u2019Amiens, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Dina","sequence":"additional","affiliation":[{"name":"CHU de Caen, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Anne","family":"Trabaud","sequence":"additional","affiliation":[{"name":"H\u00f4pital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Le Guillou-Guillemette","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, CHU Angers, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Vallet","sequence":"additional","affiliation":[{"name":"CHRU La Cavale Blanche, Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Signori-Schmuck","sequence":"additional","affiliation":[{"name":"CHU Grenoble-Alpes, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Maillard","sequence":"additional","affiliation":[{"name":"CHU de Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Ferre","sequence":"additional","affiliation":[{"name":"CHU Nantes, Laboratoire de Virologie, CIC INSERM 143, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"INSERM, IAME, UMR 1137, F-75018 Paris, France; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, F-75018 Paris, France; AP-HP, H\u00f4pital Bichat, Laboratoire de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-3522","authenticated-orcid":false,"given":"Philippe","family":"Flandre","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ANRS AC43 Resistance Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2019042309333166000_dkz021-B1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2019042309333166000_dkz021-B2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333166000_dkz021-B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"2019042309333166000_dkz021-B4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J Virol"},{"key":"2019042309333166000_dkz021-B5","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"2019042309333166000_dkz021-B6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2019042309333166000_dkz021-B7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019042309333166000_dkz021-B8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/cid\/ciy228","article-title":"Emergence of integrase resistance mutations during initial therapy containing dolutegravir","volume":"67","author":"Fulcher","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019042309333166000_dkz021-B9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"2019042309333166000_dkz021-B10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2019042309333166000_dkz021-B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2019042309333166000_dkz021-B12","first-page":"7086","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333166000_dkz021-B13","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"2019042309333166000_dkz021-B14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","article-title":"Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants","volume":"15","author":"Smith","year":"2018","journal-title":"Retrovirology"},{"key":"2019042309333166000_dkz021-B15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jmv.20522","article-title":"Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance","volume":"78","author":"Descamps","year":"2006","journal-title":"J Med Virol"},{"key":"2019042309333166000_dkz021-B16","first-page":"17","article-title":"HIV treatment and prevention: an overview of recommendations from the IAS-USA antiretroviral guidelines panel","volume":"25","author":"Volberding","year":"2017","journal-title":"Top Antivir Med"},{"key":"2019042309333166000_dkz021-B17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019042309333166000_dkz021-B18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B19","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase\u2013DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333166000_dkz021-B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"2019042309333166000_dkz021-B21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"2019042309333166000_dkz021-B22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"2019042309333166000_dkz021-B23","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B24","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B25","first-page":"123","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"Ma\u00efga","year":"2009","journal-title":"Antivir Ther"},{"key":"2019042309333166000_dkz021-B26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mespl\u00e8de","year":"2013","journal-title":"Retrovirology"},{"key":"2019042309333166000_dkz021-B27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01695-17","article-title":"Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1","volume":"61","author":"Hassounah","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333166000_dkz021-B28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dku474","article-title":"G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance","volume":"70","author":"Munir","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B29","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B30","article-title":"Resistance to HIV integrase inhibitors: about R263K and E157Q mutations","volume":"10","author":"Charpentier","year":"2018","journal-title":"Viruses"},{"key":"2019042309333166000_dkz021-B31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jac\/dkx511","article-title":"Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen","volume":"73","author":"Charpentier","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/QAD.0000000000001616","article-title":"The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro","volume":"31","author":"Saladini","year":"2017","journal-title":"AIDS"},{"key":"2019042309333166000_dkz021-B33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkw109","article-title":"Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity","volume":"71","author":"Anstett","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019042309333166000_dkz021-B34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jcv.2018.06.012","article-title":"Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): durability and virological response in a large Italian HIV drug resistance network (ARCA)","volume":"105","author":"Rusconi","year":"2018","journal-title":"J Clin Virol"},{"key":"2019042309333166000_dkz021-B35","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"2019042309333166000_dkz021-B36","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1128\/AAC.05181-14","article-title":"Combination of the R263K and M184I\/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity","volume":"59","author":"Singhroy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309333166000_dkz021-B37","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","article-title":"The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","volume":"30","author":"Oliveira","year":"2016","journal-title":"AIDS"},{"key":"2019042309333166000_dkz021-B38","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"MBio"},{"key":"2019042309333166000_dkz021-B39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J Infect Dis"},{"key":"2019042309333166000_dkz021-B40","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/infdis\/jiy474","article-title":"Human immunodeficiency virus resistance to dolutegravir: are we looking in the wrong place?","volume":"218","author":"Darcis","year":"2018","journal-title":"J Infect Dis"},{"key":"2019042309333166000_dkz021-B41","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00623-18","article-title":"Reply to Das and Berkhout, \u2018How polypurine tract changes in the HIV-1 RNA genome can cause resistance against the integrase inhibitor dolutegravir\u2019","volume":"9","author":"Malet","year":"2018","journal-title":"MBio"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/5\/1368\/28501287\/dkz021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T22:18:59Z","timestamp":1573683539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/5\/1368\/5353171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,20]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz021","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,2,20]]}}}